If your child has symptoms of JIA and has an inadequate response or intolerance to other JIA treatment medications (e.g. Disease Modifying Anti-Rheumatic Drugs [DMARDs] including biologics, or non-steroidal anti-inflammatory drugs [NSAIDs]), you and your child may be interested in learning more about a clinical study being done to assess the effects of an investigational medication in children suffering from JIA.
Juvenile Idiopathic Arthritis is the most common form of arthritis in children and adolescents. It is defined as persistent arthritis in one or more joints that begins before age 16 and lasts at least 6 weeks.
JIA is an autoimmune disorder, meaning the body’s own immune system is attacking tissues in the joints and sometimes other parts of the body. It’s unknown why this happens, but both heredity and environment seem to play a role.
The purpose of this study is to evaluate the efficacy and safety of an investigational medication in reducing the symptoms of JIA in children and adolescents.
Your son or daughter may be eligible to participate in this study if they: